Why Join?

As a result of Covid-19, supply shortages in the industry are resulting in longer lead times for Protein A resins. For early-phase antibody therapeutics, these can be as high as 8 months.

We know that keeping your process moving is vital now, more than ever, so we have have introduced the Protein A Resin Urgent Supply Scheme, specifically for biopharmaceutical developers of early-phase Covid-19 treatments. This is a dedicated supply platform which guarantees delivery of Protein A resin to your site within weeks, not months. 

By registering your interest, you will receive guaranteed, immediate access to off-the-shelf, pilot-scale volumes of best-in-class Protein A resins at dedicated, fixed prices. Whether you require bulk resin or pre-packed columns, our expedited lead times will ensure your processing goals are met efficiently and on-schedule.
 
MEMBER BENEFITS

  • Shortest lead times in the industry
  • Direct drop-in replacement resins will not impact your existing process parameters
  • Fully validated and scaled-up performance data
  • Full regulatory support
  • Dedicated, one-to-one applications support from our UK-based team

HOW ARE PRAESTO® RESINS CURRENTLY BEING USED WORLDWIDE? (click to enlarge)

SECURE, UK-BASED MANUFACTURE

Our Praesto® agarose resin manufacturing facility is one of largest of its kind in the world, and is capable of supplying one-third of all global demand for these crucial bioprocessing resins. To support the global effort against Covid-19, we have pre-allocated expedited manufacturing lots at this UK-based facility specifically for biopharmaceutical developers of early-phase Covid-19 antibody treatments. This means we can supply best-in-class resins at the shortest lead times of any global supplier. 

Significant investments into expansion and process improvements in recent years provides a streamlined, secure production of best-in-class Protein A resins. Our state-of-the-art plant was specifically built to address growing supply concerns within the biopharmaceutical industry, so is strategically positioned to provide global support during this time.

*MabSelect and MabSelect SuRe are registered trademarks of Cytiva, formerly GE Healthcare Life Sciences